TABLE 4.
Interaction parameters (I10, I50, I90) for 10, 50 and 90% inhibition of DNA synthesis of wt and mutant HIV-1 RT by combinations of NNRTIs and l-(β)-NRTIsa
| RT | Drug (d1-d2)b | Mean ± SD
|
|||||
|---|---|---|---|---|---|---|---|
| Econ (%) | D1 (μM) | D2 (μM) |
I
|
||||
| 10 | 50 | 90 | |||||
| wt | NVP–l-dTTP | 95 ± 7 | 0.25 ± 0.02 | 34.5 ± 0.1 | 0.94 ± 0.02 | ||
| wt | EFV–l-dTTP | 103 ± 5 | 0.03 ± 0.005 | 44.5 ± 0.5 | 1.1 ± 0.01 | ||
| wt | EFV–l-ddCTP | 91 ± 0.5 | 0.013 ± 0.001 | 7 ± 0.5 | 0.96 ± 0.02 | 0.62 ± 0.01 | |
| wt | EFV–l-ddCTP | 101 ± 5 | 0.016 ± 0.001 | 8.95 ± 0.05 | 1.2 ± 0.1 | 0.97 ± 0.02 | 0.66 ± 0.01 |
| L100I | EFV–l-ddCTP | 93 ± 5 | 0.05 ± 0.001 | 26.3 ± 0.1 | 1.1 ± 0.1 | 0.88 ± 0.02 | 0.75 ± 0.01 |
a
I10, I50, and I90, interaction index at 10, 50, and 90% inhibition of RT activity, respectively; Econ, estimated parameter for the control effect in the absence of the drug; D1 and D2, dose of inhibitors giving 50% inhibiton of RT activity when tested in the combination (D1 + D2). For details see Materials and Methods.
b
NVP, nevirapine; EFV, efavirenz; d1 and d2, drugs 1 and 2 in the combination.